Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): protocol for a randomized controlled trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tuberculous meningitis is the most severe form of tuberculosis. Mortality for untreated tuberculous meningitis is 100%. Despite the introduction of antibiotic treatment for tuberculosis the mortality rate for tuberculous meningitis remains high; approximately 25% for HIV-negative and 67% for HIV positive patients with most deaths occurring within one month of starting therapy. The high mortality rate in tuberculous meningitis reflects the severity of the condition but also the poor antibacterial activity of current treatment regimes and relatively poor penetration of these drugs into the central nervous system. Improving the antitubercular activity in the central nervous system of current therapy may help improve outcomes. Increasing the dose of rifampicin, a key drug with known poor cerebrospinal fluid penetration may lead to higher drug levels at the site of infection and may improve survival. Of the second generation fluoroquinolones, levofloxacin may have the optimal pharmacological features including cerebrospinal fluid penetration, with a ratio of Area Under the Curve (AUC) in cerebrospinal fluid to AUC in plasma of >75% and strong bactericidal activity against Mycobacterium tuberculosis. We propose a randomized controlled trial to assess the efficacy of an intensified anti-tubercular treatment regimen in tuberculous meningitis patients, comparing current standard tuberculous meningitis treatment regimens with standard treatment intensified with high-dose rifampicin and additional levofloxacin. METHODS/DESIGN: A randomized, double blind, placebo-controlled trial with two parallel arms, comparing standard Vietnamese national guideline treatment for tuberculous meningitis with standard treatment plus an increased dose of rifampicin (to 15 mg/kg/day total) and additional levofloxacin. The study will include 750 patients (375 per treatment group) including a minimum of 350 HIV-positive patients. The calculation assumes an overall mortality of 40% vs. 30% in the two arms, respectively (corresponding to a target hazard ratio of 0.7), a power of 80% and a two-sided significance level of 5%. Randomization ratio is 1:1. The primary endpoint is overall survival, i.e. time from randomization to death during a follow-up period of 9 months. Secondary endpoints are: neurological disability at 9 months, time to new neurological event or death, time to new or recurrent AIDS-defining illness or death (in HIV-positive patients only), severe adverse events, and rate of treatment interruption for adverse events. DISCUSSION: Currently very few options are available for the treatment of TBM and the mortality rate remains unacceptably high with severe disabilities seen in many of the survivors. This trial is based on the hypothesis that current anti-mycobacterial treatment schedules for TBM are not potent enough and that outcomes will be improved by increasing the CSF penetrating power of this regimen by optimising dosage and using additional drugs with better CSF penetration. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number ISRCTN61649292.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Agresti, A. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/0471249688 · Cited by 6,746
Cited by
Tuberculous meningitis: more questions, still too few answers
Thwaites, G. E., van Toorn, R., & Schoeman, J. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70168-6 · Cited by 482
Ruslami, R., Ganiem, A. R., Dian, S., Apriani, L., Achmad, T. H., van der Ven, A. J., Borm, G., Aarnoutse, R. E., & van Crevel, R. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70264-5 · Cited by 344
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Beardsley, J., Wolbers, M., Kibengo, F. M., Ggayi, A.-B. M., Kamali, A., Cuc, N. T. K., Binh, T. Q., Chau, N. V. V., Farrar, J., Merson, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509024 · Cited by 315
Self-citationIntensified Antituberculosis Therapy in Adults with Tuberculous Meningitis
Heemskerk, A. D., Bang, N. D., Mai, N. T. H., Chau, T. T. H., Phu, N. H., Loc, P. P., Chau, N. V. V., Hien, T. T., Dung, N. H., Lan, N. T. N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507062 · Cited by 310
Self-citationEvaluation of GeneXpert MTB/RIF for Diagnosis of Tuberculous Meningitis
Nhu, N. T. Q., Heemskerk, D., Thu, D. D. A., Chau, T. T. H., Mai, N. T. H., Nghia, H. D. T., Loc, P. P., Ha, D. T. M., Merson, L., Thinh, T. T. V., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01834-13 · Cited by 244
“The full protocol of that trial is reported elsewhere (International Standard Randomized Controlled Trial Number ISRCTN61649292) (32).”
MethodSelf-citation
Metadata
- Authors
- Heemskerk, D., Day, J., Chau, T. T. H., Dung, N. H., Yen, N. T. B., Bang, N. D., Merson, L., Olliaro, P., Pouplin, T., Caws, M., Wolbers, M., & Farrar, J.
- Venue
- Trials
- Published
- 2011-02-02
- Volume
- 12
- Issue
- 1
- Pages
- 25-25
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2131178604
- Cited by
- 70
- References
- 1
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/1745-6215-12-25
- The paper
- Heemskerk, D., Day, J., Chau, T. T. H., Dung, N. H., Yen, N. T. B., Bang, N. D., Merson, L., Olliaro, P., Pouplin, T., Caws, M., Wolbers, M., & Farrar, J. (2011). Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/1745-6215-12-25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.